AtriCure to Announce Third Quarter 2021 Financial Results

Rhea-AI Summary

AtriCure, a leader in atrial fibrillation (Afib) treatments, has announced the release of its third quarter 2021 financial results on November 3, 2021. A conference call will take place at 4:30 p.m. ET to discuss these results, which can be accessed via phone or through a live audio webcast. AtriCure's technologies, including the Isolator® Synergy™ Ablation System and AtriClip® products, are critical in treating over 33 million people affected by Afib globally. These innovations position AtriCure as a prominent player in the medical device market.

Positive

• AtriCure's Isolator® Synergy™ Ablation System received FDA approval for persistent Afib treatment.
• AtriCure's AtriClip® products are the most widely sold LAA management devices globally.

Negative

• None.

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release third quarter 2021 financial results on Wednesday, November 3, 2021.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, November 3, 2021 to discuss its third quarter 2021 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 5139213. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator^® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip^® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE^® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005019/en/

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com

Lynn Pieper Lewis

Gilmartin Group

Investor Relations

(415) 937-5402

lynn@gilmartinir.com

Source: AtriCure, Inc.

FAQ

When will AtriCure release its third quarter 2021 financial results?

AtriCure will release its third quarter 2021 financial results on November 3, 2021.

What time is the AtriCure conference call for Q3 2021 results?

The conference call for AtriCure's Q3 2021 results will be held at 4:30 p.m. Eastern Time on November 3, 2021.

How can I access AtriCure's Q3 2021 earnings call?

You can access AtriCure's Q3 2021 earnings call by calling (844) 884-9951 for domestic callers or (661) 378-9661 for international callers, using conference ID number 5139213, or via a live audio webcast on their corporate website.

What is AtriCure's role in treating atrial fibrillation?

AtriCure provides innovative technologies for the treatment of atrial fibrillation (Afib) and related conditions.